Peakdale Molecular, UK, and BioLeap, US, have entered into a collaboration to design and synthesise highly focused kinase libraries for drug discovery, with the initial project targeting the c-Abl Tyrosine Kinase. By combining BioLeap’s leading edge computational fragment-based design capabilities with Peakdale’s innovative chemistry expertise, the collaboration is set to produce drug like compounds that produce high quality, patentable leads for the pharmaceutical industry.
